Cathy Tangen contributes to international study, finding on again-off again prostate cancer treatment has quality of life benefits, but continuous therapy improves overall survival
June 4, 2012
Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous androgen-deprivation therapy (also known as hormone therapy) than on intermittent therapy, according to a 17-year study led by SWOG (formerly Southwest Oncology Group), a cancer research cooperative group.
Trial analysis by PHS investigators reveals supplement hazard in largest-ever prostate cancer prevention study
Nov. 21, 2011
Men who took 400 international units of vitamin E daily had more prostate cancers compared to men who took a placebo, according to an updated review of data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT). The Fred Hutchinson Cancer Research Center Public Health Sciences Division's Phyllis Goodman and Drs. Cathy Tangen and Gary Goodman (whose primary appointment is at the Swedish Cancer Institute) analyzed the data for this study.